Deliver Your News to the World

Breakthrough In Indexing Set To Deliver Drug Literature In Half the Time


Amsterdam, The Netherlands, 22 January, 2007 – Today Elsevier announced it has developed a new method for indexing full-text information about individual drugs. The new technique will significantly reduce the time pharmaceutical companies have to spend keeping up-to-date with research about their own and competing products. The benefits of ‘Drug-Specific Indexing’ will be evident in Elsevier’s forthcoming service Emscopes™.

A new kind of online product literature database, Emscopes promises to combine tailored content selected for each customer, with Elsevier’s new standard drug-specific indexing process and a simple search interface. Available from February 2007, Emscopes will provide up-to-date, instant and comprehensive reports of the research literature on any drug.

The ’Drug-Specific Indexing’ goes deep into the full text of every article to extract detailed information for each drug, such as adverse drug reactions, drug comparisons, administration routes and dosage. Bringing together this data in Emscopes, means that anyone in the company – from Medical Advisors to Drug Safety to Sales & Marketing – will effectively have the full-text read and summarised for them.

Martin O’Malley, Managing Director of Elsevier’s corporate division says “for decades Elsevier has provided top-quality abstracting and indexing services to the pharmaceutical market. EMBASE for example is renowned for its superior drug indexing and the EMTREE thesaurus, and is used by clinical researchers in virtually every major pharmaceutical company in the world. We now plan to deliver an ‘off-the-shelf’ solution for companies to monitor the relevant published research at an extraordinary level of accuracy.”

Senior Product Manager, Tessa Sterkenburg, explains Elsevier’s thinking behind the technology: “We have a team of people reading the full-text to extract relevant drug information. Now that this is embedded in our regular indexing we can process new records very quickly to give the utmost currency, and we can offer the highest precision indexing cost-effectively.”


About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier’s 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect, MD Consult, Scopus, bibliographic databases, and online reference works.

Elsevier is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier’s ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.